CLEO Diagnostics Ltd (AU:COV) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cleo Diagnostics Ltd is expanding its ovarian cancer trial with the inclusion of Siles Health, a leading women’s health specialist network in Australia. This collaboration aims to enhance clinical insights and support market adoption of CLEO’s innovative blood test for early ovarian cancer detection. By integrating Siles Health’s expertise, CLEO is poised to advance its trial strategy and increase market awareness for its potentially life-saving diagnostic tool.
For further insights into AU:COV stock, check out TipRanks’ Stock Analysis page.